Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1438-1444

  Halperin, Scott A ^a   Ward, Brian J ^b   Dionne, Marc ^c   Langley, Joanne M ^a   McNeil, Shelly A ^a   Smith, Bruce ^a   MacKinnon Cameron, Donna ^a   Heyward, William L ^d   Martin, J Tyler ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d Dynavax Technologies Corporation   (United States)

Author keywords

Hepatitis B; Hepatitis B vaccine; Immunogenicity; Immunostimulatory sequences; Nonresponder; Randomized trial

Indexed keywords

HEPATITIS B SURFACE ANTIGEN 1018 VACCINE; HEPATITIS B VACCINE; HEPATITIS VACCINE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE WARMTH; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VACCINE FAILURE; VOMITING;

HEPATITIS B; HEPATITIS B VACCINE; IMMUNOGENICITY; IMMUNOSTIMULATORY SEQUENCES; NONRESPONDER; RANDOMIZED TRIAL;

ADOLESCENT; ADULT; ANTIBODY FORMATION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; VACCINATION; YOUNG ADULT;

EID: 84880853688     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24256     Document Type: Conference Paper

References (39)

1. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2009; 84:405-19; PMID:19817017.
2. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87(Suppl 3a):14S-20S; PMID:2528292; http://dx.doi.org/10.1016/0002-9343(89)90525-1.
3. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766-9; PMID:2530289; http://dx.doi.org/10.1093/infdis/160.5.766.
4. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 1999:158-82.
5. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179:489-92; PMID:9878036; http://dx.doi.org/10.1086/314578.
6. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am 2006; 20:27-45; PMID:16527647; http://dx.doi.org/10.1016/j.idc.2006.01.004.
7. Cardell K, Åkerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198:299-304; PMID:18544037; http://dx.doi.org/10.1086/589722.
8. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87(3A):36S-40S; PMID:2528297; http://dx.doi.org/10.1016/0002-9343(89) 90530-5.
9. Höhler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360:991-5; PMID:12383669; http://dx.doi.org/10.1016/S0140-6736(02)11083-X.
10. Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61; PMID:22298301.
11. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14; PMID:2941687; http://dx.doi.org/10.1056/NEJM198607243150401.
12. Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644-9; PMID:12399191; http://dx.doi.org/10.1016/S0264-410X(02) 00397-3.
13. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in nonand low responders to conventional vaccine. Vaccine 2006; 24:2781-9; PMID:16455169; http://dx.doi.org/10.1016/j.vaccine.2006.01.007.
14. Goldwater PN. Randomized, comparative trial of 20 micrograms vs. 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997; 15:353-6; PMID:9141204; http://dx.doi.org/10.1016/S0264-410X(96)00202-2.
15. Lin C, Zhu J, Zheng Y, Chen Y, Wu Z, Chong Y, et al. Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders. J Infect 2010; 60:264-70; PMID:20138189; http://dx.doi.org/10. 1016/j.jinf.2010.01.011.
16. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 21:4604-8; PMID:14575774; http://dx.doi.org/10.1016/S0264-410X(03)00447-X.
17. Zuckerman JN, Zuckerman AJ, Symington I, Du W, Williams A, Dickson B, et al.; UK Hepacare Study Group. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 2001; 34:798-802; PMID:11584378; http://dx.doi.org/10.1053/jhep.2001.27564.
18. Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine 2012; 30:6734-7; PMID:22981848; http://dx.doi.org/10.1016/j.vaccine. 2012.08.074.
19. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 1996; 5:303-10; PMID:8885863; http://dx.doi.org/10.1016/S1074-7613(00) 80256-3.
20. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209-13; PMID:2423876; http://dx.doi.org/10.1038/321209a0.
21. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j. immuni.2010.10.002.
22. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461-7; PMID:12744879; http://dx.doi.org/10.1016/S0264-410X(03)00045-8.
23. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24:20-6; PMID:16198027; http://dx.doi.org/10.1016/j.vaccine.2005. 08.095.
24. Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxy-ribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30:2556-63; PMID:22326642; http://dx.doi.org/10.1016/j.vaccine.2012.01.087.
25. Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostim-ulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012; 30:5445-8; PMID:22704926; http://dx.doi.org/10.1016/j.vaccine.2012.05.074.
26. Clemens R, Sänger R, Kruppenbacher J, Höbel W, Stanbury W, Bock HL, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997; 15:349-52; PMID:9141203; http://dx.doi.org/10.1016/ S0264-410X(96)00205-8.
27. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b revaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12:1204-11; PMID:9198052; http://dx.doi.org/10.1093/ndt/12.6.1204.
28. Valats JC, Tuaillon E, Funakoshi N, Hoa D, Brabet MC, Bolloré K, et al. Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 2010; 28:6411-6; PMID:20682363; http://dx.doi.org/10.1016/j.vaccine.2010.07.058.
29. Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y, et al. Tolllike receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 2011; 29:706-11; PMID:21111021; http://dx.doi.org/10.1016/j.vaccine.2010.11.023.
30. Velu V, Saravanan S, Nandakumar S, Shankar EM, Vengatesan A, Jadhav SS, et al. Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J Gastroenterol 2008; 14:3534-40; PMID:18567083; http://dx.doi.org/10.3748/wjg.14.3534.
31. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344:856-7; PMID:7916403; http://dx.doi.org/10.1016/S0140-6736(94)92829-0.
32. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9; PMID:7700380; http://dx.doi.org/10.1038/374546a0.
33. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879-83; PMID:8610135; http://dx.doi.org/10.1073/pnas.93.7.2879.
34. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-54; PMID:9256274;http://dx.doi.org/10.1038/nm0897-849.
35. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 1986; 105:356-60; PMID:2943202.
36. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708-12; PMID:2528067; http://dx.doi.org/10.1056/NEJM198909143211103.
37. Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, Chen DS, et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 1993; 11:1437-40; PMID:8310763; http://dx.doi.org/10.1016/0264-410X(93)90173-U.
38. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51:593-604; PMID:9694351; http://dx.doi.org/10.1111/j.1399-0039.1998.tb03001.x.
39. McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997; 50:8-14; PMID:9243749; http://dx.doi.org/10. 1111/j.1399-0039.1997.tb02827.x.